Peptides (maximum 4) among 24 (each 8 for HLA-A2, -A24, and -A3 super type) peptides, which were identified as vaccine candidates for cancer patients, are administered with Freund incomplete adjuvant.
Sponsors
Department of Immunology, Kurume University School of Medicine
Conditions
Advanced cancer patients who are refractory to standard therapies for cancerAdvanced pediatric malignant glioma patients who are refractory to standard therapies
Phase 1
Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced cancer patients
Active, not recruitingJPRN-UMIN000000619
Start: 2007-03-01Target: 40Updated: 2026-06-29
Phase I clinical trial of pan-HLA type personalized peptide vaccine for advanced pediatric malignant glioma patients
Active, not recruitingJPRN-UMIN000000760
Start: 2007-06-01Target: 10Updated: 2026-06-29